Share This Author
Clinical Pharmacokinetics of Mycophenolate Mofetil
The pharmacokinetics of patients with renal transplants compared with those of healthy individuals were similar after oral mycophenolate mofetil, but there was a progressive decrease in MPAG clearance as glomerular filtration rate (GFR) declined.
Pharmacokinetics of mycophenolate mofetil (RS61443): a short review.
The ability to relate plasma MPA concentrations to efficacy through the PK/PD correlation implies that, unlike for many other drugs, plasma PK has direct relevance to the clinical outcome.
The pharmacokinetic‐pharmacodynamic relationship for mycophenolate mofetil in renal transplantation
Pharmacokinetics and Bioavailability of Mycophenolate Mofetil in Healthy Subjects after Single‐Dose Oral and Intravenous Administration
A randomized, crossover study of 12 healthy volunteers was conducted with single, 1.5‐g doses of mycophenolate mofetil (MMF), a prodrug of myCophenolic acid (MPA), after oral and intravenous administration, finding that MMF administered orally undergoes rapid, complete absorption and essentially complete presystemic deesterification.
Mycophenolic Acid Area under the Curve Values in African American and Caucasian Renal Transplant Patients Are Comparable
A statistically significant decrease in MPA AUC and increase in oral apparent clearance were observed in renally impaired patients regardless of ethnicity on days 4, and 4 and 7, respectively, suggesting uremia‐induced increased MPA free fraction, leading to a temporary increased clearance for this restrictively cleared drug.
A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney…
MPA Cpredose and MPA AUC are significantly related to the incidence of biopsy-proven rejection after kidney transplantation, whereas MMF dose is significantly relatedto the occurrence of adverse events.
Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix
Data show that an oral nonpeptide GnRH antagonist, elagolix, can achieve dose-related pituitary and gonadal suppression in premenopausal women and may prove to be useful for management of nonmalignant reproductive hormone-dependent disease states.
Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of…
- A. Nicholls
- MedicineClinical biochemistry
- 1 July 1998
The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function
A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a…
Short term enlimomab induction therapy after renal transplantation did not reduce the rate of acute rejection or DGF and there was no statistically significant difference between the incidences between the two groups.